Trial intelligence / Profile preview

Lazertinib for EGFR-mutated NSCLC in TKI-naïve patients (single-arm phase II)

KCT0007795Phase 2Active, not recruiting

Sponsor

Yuhan

Start

Jan 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1